Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ProtoKinetix, Inc. (OTC: PKTX).

Full DD Report for PKTX

You must become a subscriber to view this report.


Recent News from (OTC: PKTX)

Daily Insider Ratings Round Up 1/16/18: CHN, SIG, PKTX, IGSC, PGLC
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: January, 18 2018 10:15
ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP(TM) on Monoclonal Antibody Production and Bone Marrow Recovery
ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) is pleased to announce that it has entered into a research agreement with The University of British Columbia (UBC), under the direction of principal investigator Dr. Kelly McNagny, Professor,...
Source: Business Wire
Date: January, 10 2018 09:15
The Effects of ProtoKinetix' Anti-Aging Glycopeptide (AAGP(TM)) on Immune Cell Banking and Functions Relevant to Immunotherapy
ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) is pleased to provide a scientific update on immune cell banking and functions relevant to immunotherapy using AAGP™ in collaboration with Proactive Immune Sciences. Earlier in 2017, P...
Source: Business Wire
Date: November, 16 2017 12:17
Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery
ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) is pleased to provide a scientific update to its stockholders. The Company is exploring the following areas for the use of its AAGP™ family of molecules: Presently at the Universi...
Source: Business Wire
Date: October, 17 2017 09:15
ProtoKinetix and Proactive Immune Sciences Announce a Joint Research Collaboration Using AAGP(TM) in Immune Cell Cryopreservation Testing
ProtoKinetix , Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") ( www.protokinetix.com ) and Proactive Immune Sciences ( www.proactiveimmunesciences.com ) today announce that they have entered into a joint research collaboration. The goal of the research will be to test the effe...
Source: Business Wire
Date: June, 05 2017 10:37
ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP(TM)
ProtoKinetix , Incorporated (OTC:PKTX) (the "Company" or "ProtoKinetix") ( www.protokinetix.com ) today announces that it has completed the first year of retinal replacement therapy trials on animals and the results are encouraging enough to proceed to a second phase of testing. There a...
Source: Business Wire
Date: May, 24 2017 09:30
ProtoKinetix Announces Start of Phase 1 & Phase 2 Clinical Trials for the use of AAGP(TM) PKX-001 Treated Islet Cells in the Treatment of Type 1 Diabetes
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") ( www.protokinetix.com ) today announced the start of a Phase 1 first-in-human clinical trial of AAGP™ PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type 1 di...
Source: Business Wire
Date: March, 09 2017 09:15
ProtoKinetix Updates Testing Progress on Neuronal Retinal Cells in Living Tissue for the Treatment of Macular Degeneration
ProtoKinetix , Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") ( www.protokinetix.com ) updates its stockholders on the testing of neuronal retinal cells in living tissue at the University of British Columbia (“UBC”) under the guidance of Dr. Gregory-Evans. As...
Source: Business Wire
Date: February, 07 2017 13:22
ProtoKinetix Announces Investigator Sponsored Human Clinical Trial Application Using AAGP(TM) Has Been Approved by Health Canada
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") ( www.protokinetix.com ) today announced that the Governors of the University of Alberta have received a “No Objection Letter” from Health Canada to its Clinical Trial Application entitled: “Clini...
Source: Business Wire
Date: January, 24 2017 09:15
ProtoKinetix, Incorporated Announces Investigator Sponsored Clinical Trial Submitted to Health Canada for the use of AAGP(TM) in the Treatment of Type 1 Diabetes
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") ( www.protokinetix.com ) today announced that the Governors of the University of Alberta have submitted an Investigational Testing Authorization application to commence clinical studies in Canada. This authorization w...
Source: Business Wire
Date: January, 17 2017 09:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-210.0720.0720.0720.0729,100
2018-08-200.080.080.080.0818,000
2018-08-170.07850.07850.07850.078510,000
2018-08-150.0730.080.080.0712,968
2018-08-14N/A0.075N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1665,742125,87052.2301Short
2018-08-1510,00012,96877.1129Short
2018-08-137,62453,64814.2112Cover
2018-08-1091,335128,00871.3510Short
2018-08-0921,60021,600100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PKTX.


About ProtoKinetix, Inc. (OTC: PKTX)

Logo for ProtoKinetix, Inc. (OTC: PKTX)

lt p gt ProtoKinetix, Incorporated ProtoKinetix or the Company is a research and development stage biotechnology company focused on scientific medical research of AFGPs Anti Freeze Glycoproteins or anti aging glycoproteins, and has developed and patented a family of hyper stable, potent glycopeptides trademarked as AAGPs that enhance the therapeutic results and can reduce the cost of stem cell medicine. Due to the anti inflammatory effect of AAGPTM molecules, the Company is currently in the process of directing major efforts to target the direct treatment of diseases that have a major inflammatory component. lt /p gt

 

Contact Information

 

 

Current Management

  • Clarence E. Smith / CEO, President
  • Michael Guzzetta / CFO
  • Clarence E. Smith / Chairman
  • Edward P. McDonough /

Current Share Structure

  • Market Cap: $14,518,565 - 03/09/2018
  • Authorized: 400,000,000 - 02/28/2018
  • Issue and Outstanding: 254,711,673 - 02/28/2018
  • Float: 138,759,876 - 05/28/2015

 


Recent Filings from (OTC: PKTX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 10 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 22 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: January, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 15 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 13 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 09 2017
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: September, 21 2017
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: September, 12 2017

 

 


Daily Technical Chart for (OTC: PKTX)

Daily Technical Chart for (OTC: PKTX)


Stay tuned for daily updates and more on (OTC: PKTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PKTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PKTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of PKTX and does not buy, sell, or trade any shares of PKTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/